CFI rs141853578: What Your Genotype Means for AMD Risk
The rs141853578 variant is a rare genetic change in the CFI gene that results in a p.Gly119Arg amino acid substitution. Research indicates that this specific variant is associated with an increased risk of developing advanced age-related macular degeneration (AMD).
What each genotype means
Typical AMD risk
You carry two copies of the common C allele at rs141853578 in the CFI gene. This genotype is associated with normal baseline complement factor I expression and does not carry the elevated risk for advanced age-related macular degeneration linked to the rare missense variant. Your overall risk for macular degeneration remains governed by general lifestyle and other common genetic factors.
Carried by over 99.8% of individuals globally across most major continental populations.
Elevated advanced AMD risk
You carry one copy of the rare T risk allele, which encodes the p.Gly119Arg alteration in complement factor I. Published research has shown that this heterozygous genotype is statistically associated with reduced serum factor I levels and a significantly higher odds of developing advanced age-related macular degeneration. However, carrying this variant is not a clinical diagnosis and does not guarantee the disease will develop, as overall outcomes depend on age, environmental factors, and additional genetic influences.
Found in fewer than 1 in 1,000 individuals globally in gnomAD, though frequency is slightly higher in European cohorts enriched for macular degeneration.
Elevated advanced AMD risk
You carry two copies of the rare T risk allele at rs141853578 in the CFI gene. Having two copies of this variant is linked to substantially reduced complement factor I activity and an increased statistical predisposition to advanced age-related macular degeneration. Evidence for this homozygous state is extremely limited due to its rarity in the general population, and it should not be taken as a medical diagnosis.
Extremely rare worldwide, occurring in far fewer than 1 in 100,000 individuals in large reference datasets such as gnomAD.
Understanding the rs141853578 Variant
The rs141853578 variant is a specific genetic change located within the CFI gene on chromosome 4. In scientific literature, this variant is often referred to as p.Gly119Arg, describing a substitution where the amino acid glycine is replaced by arginine at position 119 of the protein. This change is classified as a missense mutation, meaning it alters the genetic code in a way that changes the resulting protein's structure. Because this variant is rare, it is not typically included in standard, broad-spectrum genetic screening panels. Its identification usually requires targeted sequencing of the CFI gene. Understanding such variants is part of a broader effort to map the genetic architecture of complex, multifactorial conditions like age-related macular degeneration (AMD), where multiple rare and common genetic factors contribute to an individual's overall risk profile.
The Role of the CFI Gene
The CFI gene provides instructions for producing a protein called complement factor I. This protein acts as a critical regulator of the complement system, which is a part of the body's innate immune response. Complement factor I functions as a serine protease that helps prevent the complement system from becoming overactive. By breaking down specific proteins like C3b, it ensures that the immune system does not inadvertently damage healthy tissues. When the CFI gene carries a functional variant like rs141853578, the resulting factor I protein may be produced at lower levels or exhibit reduced activity. This impairment can lead to an unregulated or overactive complement system, which is thought to contribute to the chronic inflammation and tissue damage observed in the retina of individuals with advanced age-related macular degeneration.
Research and Evidence Strength
The association between rs141853578 and advanced AMD is supported by several studies, including targeted sequencing efforts that identified this variant in cohorts of patients with the condition. Research has demonstrated that individuals carrying this variant often show lower levels of circulating serum factor I protein compared to those without the variant. Statistical analyses have linked this genetic change to a significantly higher odds ratio for developing advanced AMD. However, the evidence is considered limited in terms of its predictive power for the general population because the variant is extremely rare. While the biological mechanism—reduced regulation of the complement system—is well-supported, the variant's presence alone does not guarantee the development of disease. AMD is a complex condition influenced by a combination of genetics, age, and environmental factors, such as smoking and diet.
Population Frequency
The rs141853578 variant is rare, with a minor allele frequency of less than 0.1% in global populations according to gnomAD data. It has been observed to be enriched in specific European cohorts studied for AMD. Because of its low frequency, most individuals do not carry this variant. Its distribution is not uniform across all ancestral groups, and researchers continue to study how such rare variants contribute to disease risk across diverse populations. The rarity of this variant means that large-scale studies are often required to confirm its impact, and findings from one population may not always be directly applicable to others.
What This Information Means for You
If you have been informed that you carry the rs141853578 variant, it is important to understand that this is a risk factor, not a diagnosis. Genetic risk is only one piece of the puzzle in the development of age-related macular degeneration. Many people with genetic predispositions never develop the condition, while others without these specific variants may still be affected. This information cannot be used to predict the exact timing or severity of potential vision changes. If you are concerned about your eye health, the most effective step is to schedule regular comprehensive eye exams with an ophthalmologist or optometrist. They can monitor your retinal health and discuss lifestyle modifications, such as smoking cessation or nutritional support, which are known to influence AMD progression. Always consult with a healthcare professional before making medical decisions based on genetic test results.
How common is this variant?
The rs141853578 variant is rare, with a minor allele frequency of less than 0.1% globally, though it is more frequently identified in European cohorts with AMD.
Frequently asked questions
Does having the rs141853578 variant mean I will get AMD?
No, having this variant does not mean you will definitely develop AMD. It is considered a risk factor, meaning it may increase your susceptibility, but it is not a diagnostic indicator of the disease.
What is the link between CFI and eye health?
The CFI gene produces a protein that regulates the immune system's complement pathway. When this protein is less active, it can lead to chronic inflammation in the eye, which is a known factor in the development of advanced AMD.
Should I get tested for this variant?
Genetic testing for rare variants like rs141853578 is not standard practice for the general public. You should discuss the necessity of any genetic testing with an eye care specialist or a genetic counselor based on your personal and family medical history.
Are there treatments for people with this variant?
Research is ongoing into whether individuals with CFI-related AMD might benefit from specific complement-inhibitory therapies. Currently, management of AMD focuses on regular monitoring and standard clinical treatments; consult your ophthalmologist for personalized care.
Sources & further reading
Educational information only, last refreshed 10/18/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs141853578?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29